HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add―on therapy in patients with lamivudine resistance

• Published in: Antiviral therapy 2012-01, Vol.17 (2), p.387-394
• Main Authors: JUNG WOO SHIN, SEOK WON JUNG, BO RYUNG PARK, CHANG JAE KIM, JUN BUM EUM, BYUNG GYU KIM, IN DU JEONG, BANG, Sung-Jo, NEUNG HWA PARK
• Format: Article
• Language: English
• Subjects: Adefovir; Adenine - analogs & derivatives; Adenine - pharmacology; Adenine - therapeutic use; Adult; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Biological and medical sciences; DNA; DNA, Viral - blood; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B e Antigens - blood; Hepatitis B e Antigens - immunology; Hepatitis B virus; Hepatitis B virus - drug effects; Hepatitis B virus - genetics; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - virology; Humans; Kidney Function Tests; Lamivudine; Lamivudine - pharmacology; Lamivudine - therapeutic use; Liver Function Tests; Male; Medical sciences; Middle Aged; Organophosphonates - pharmacology; Organophosphonates - therapeutic use; Pharmacology. Drug treatments; Treatment Outcome; Viral Load
• ISSN: 1359-6535; 2040-2058
• DOI: 10.3851/IMP1945

The aim of this study was to investigate the relationship between HBV DNA levels at baseline and on-treatment and the virological response at 96 weeks after adefovir add-on therapy in chronic hepatitis B (CHB) patients with lamivudine resistance. Lamivudine and adefovir combination therapy was administered to 122 CHB patients for >24 months. Virological response (HBV DNA negativity) was achieved in 53 (43.3%) and 62 patients (50.8%) at 48 and 96 weeks, respectively. The receiver operating characteristic curve analysis showed that the HBV DNA level at week 24 had a greater power (area under the receiver operating characteristic curve 0.978; 95% CI 0.949, 1.000; P